Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Massie, Barry M.; Berk, Martin R.; Brozena, Susan C.; Elkayam, Uri; Plehn, Jonathan F.; Kukin, Marrick; Packer, Milton; Murphy, Beverley E. Pearson; Neuberg, Gerald W.; Steingart, R. M.

doi:10.1161/01.cir.88.2.492

Cited by 83 publications

(22 citation statements)

References 34 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Favorable hemodynamic effects, however, may not necessarily be associated with improved prognosis in CHF. [25][26][27] The most common adverse effects, headache and worsening of heart failure, were more frequent in patients receiving the higher dosages. Indeed, headache, which usually was classified as mild, occurred in 17.9% and 28.6% of those receiving 100 mg or 300 mg of darusentan, respectively, but in none of the patients receiving 30 mg of darusentan.…”

Section: Discussionmentioning

confidence: 99%

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A ) Receptor Blockade in Chronic Heart Failure

et al. 2002

View full text Add to dashboard Cite

Background— The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of selective ET blockade is clinically beneficial is unknown. We investigated hemodynamic and neurohumoral effects of 3 weeks of treatment with various dosages of the orally available ET A antagonist darusentan in addition to modern standard therapy in patients with CHF. Methods and Results— A total of 157 patients with CHF (present or recent NYHA class III of at least 3 months duration), pulmonary capillary wedge pressure ≥12 mm Hg, and a cardiac index ≤2.6 L · min −1 · m −2 were randomly assigned to double-blind treatment with placebo or darusentan (30, 100, or 300 mg/d) in addition to standard therapy. Short-term administration of darusentan increased the cardiac index, but this did not reach statistical significance compared with placebo. The increase in cardiac index was significantly more pronounced after 3 weeks of treatment ( P <0.0001 versus placebo). Pulmonary capillary wedge pressure, pulmonary arterial pressure, pulmonary vascular resistance, and right atrial pressure remained unchanged. Heart rate, mean artery pressure, and plasma catecholamines remained unaltered, but systemic vascular resistance decreased significantly ( P =0.0001). Higher dosages were associated with a trend to more adverse events (including death), particularly early exacerbation of CHF without further benefit on hemodynamics compared with moderate dosages. Conclusions— This study demonstrates for the first time in a large patient population that 3 weeks of selective ET A receptor blockade improves cardiac index in patients with CHF. However, long-term studies are needed to determine whether ET A blockade is beneficial in CHF.

show abstract

Section: Discussionmentioning

confidence: 99%

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A ) Receptor Blockade in Chronic Heart Failure

et al. 2002

View full text Add to dashboard Cite

show abstract

“…However, drugs such as milrinone, enoximone, and flosequinan have been shown to improve symptoms at the expense of an increase in fatality. [1][2][3] Thus, evidence that a new drug improves the symptoms of heart failure is necessary but not sufficient for its acceptance into clinical use. Ideally, a new drug would increase survival and improve symptoms; at the least, it should have no effect on survival.…”

Section: Introductionmentioning

confidence: 99%

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure

et al. 1997

View full text Add to dashboard Cite

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure Hampton, J.R.; Veldhuisen, D.J.; Kleber, F.X.; Cowley, A.J.; Ardia, A.; Block, P.; Cortina, A.; Cserhalmi, L.; Follath, F.; Jensen, G.; Kayanakis, J.; Lie, K.I.; Mancia, G.; Skene, A.M. Published in: Lancet DOI:10.1016/S0140-6736(96)10488-8 Link to publicationCitation for published version (APA): Hampton, J. R., Veldhuisen, D. J., Kleber, F. X., Cowley, A. J., Ardia, A., Block, P., ... Skene, A. M. (1997). Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet, 349, 971-977. https://doi.org/10.1016/S0140-6736(96)10488-8 General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. Download date: 22 Mar 2019Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure J R Hampton, D J van Veldhuisen, F X Kleber, A J Cowley, A Ardia, P Block, A Cortina, L Cserhalmi, F Follath, G Jensen, J Kayanakis, K I Lie, G Mancia, A M Skene, for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators THE LANCET SummaryBackground Drugs that improve symptoms in patients with heart failure must also be assessed for their effects on survival. Ibopamine stimulates DA-1 and DA-2 receptors and causes peripheral and renal vasodilatation; the drug improves symptoms of heart failure. W e assessed the effect of ibopamine on survival in patients with advanced heart failure in a mult ic ent re, randomised plac ebocontrolled study.

show abstract

“…Alle disse medikamentene øker myokards energiforbruk. I behandling av både kronisk og akutt hjertesvikt har slike medikamenter vist seg å ha klart uheldige langtidseffekter i form av økt mortalitet og økt forekomst av atrieflimmer og andre arytmier (28)(29)(30)(31)(32). Tilvarende er vist når disse medikamentene brukes ved hjerteoperasjoner (33,34).…”

Section: Inotropiunclassified

Anestesi ved åpen hjertekirurgi hos voksne

Veel¹,

Bugge²,

Kirkebøen³

et al. 2010

Tidsskriftet

View full text Add to dashboard Cite

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Cited by 83 publications

References 34 publications

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A ) Receptor Blockade in Chronic Heart Failure

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A ) Receptor Blockade in Chronic Heart Failure

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure

Anestesi ved åpen hjertekirurgi hos voksne

Contact Info

Product

Resources

About

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Cited by 83 publications

References 34 publications

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart Failure

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart Failure

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure

Anestesi ved åpen hjertekirurgi hos voksne

Contact Info

Product

Resources

About

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A ) Receptor Blockade in Chronic Heart Failure

Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET _A ) Receptor Blockade in Chronic Heart Failure